News

Already in clinical trials, Reolysin, a reovirus-based therapy from Oncolytics Biotech, will soon be administered to patients with metastatic tumors in a company-sponsored phase I trial. Reoviruses are

Ceflatonin is currently undergoing examination in a phase II trial for the treatment of chronic myeloid leukemia (CML) in patients who are resistant to Gleevec. In addition to

Pending clearance by the FDA, New River expects to commence clinical trials later this year to assess the safety and efficacy of NRP290 as a treatment for acute

The study carried out at Wayne State University and the Kresge Eye Institute in Detroit has shown in laboratory animals that thymosin beta 4 (TB4) treatment promotes corneal

HEE describes the diabetes supplement as a “breakthrough nutraceutical.” The company believes the product safely and effectively addresses the three major issues of type II diabetes by reducing

The new version of the inhaled corticosteroid Pulmicort will be available in two strengths, 100g and 200g, and will be used for the treatment of asthma in adults

The Orphan Drug Act is intended to encourage the development of products for rare diseases affecting fewer than 200,000 people in the US. Callisto’s orphan drug designation entitles

The placebo-controlled dose escalation study is being conducted in Europe to investigate the safety and tolerability of inhaled CGRP in 10 healthy volunteers. The company expects to complete

The move is thought to illustrate Pfizer’s intention to offload its non-strategic assets, including the manufacture of generic drugs. Instead, the company is said to be keen to